Blue Jet Healthcare Limited CC-Mar25.pdf · 2025-05-14
Thanks for the opportunity and great set of results. The first question is on the cardiovascular intermediate product. We did about 200 odd crores in Q4. Can this be a new base and can we grow from this base in FY'26 on a quarterly basis?
Understood. So second question is on this GLP-1 intermediate molecule. Roughly what could be the opportunity size for us in this molecule? Can this also be as large as the cardiovascular intermediate or larger?